Aya Mohamed | MSc, MD 🎗· @Dr_Oncologista · X·· 2 天前评分90
正文 · 原文
PANKU-Breast01 | #ESMO26
Iza-bren significantly improved PFS in pretreated HR+/HER2− advanced #BreastCancer vs physician’s choice chemotherapy (8.2 vs 4.0 months; HR 0.41).
@OncoAlert #bcsm
610 浏览 · 19 赞 · 7 转发 · 1 回复
会议摘要
LBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.org帖内回复
- Aya Mohamed | MSc, MD 🎗@Dr_Oncologista
@OncoAlert @myESMO The benefit came with substantial grade 3 or higher toxicity (85.3%) and frequent dose reductions (64.7%). OS remains immature. A strong efficacy signal, but tolerability, long-term outcomes, and optimal sequencing remain key considerations.
来源：Aya Mohamed | MSc, MD 🎗 · x.com